3-(3,3-Dimethylbut-1-en-2-yl)pyridine | 1332508-37-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(3,3-Dimethylbut-1-en-2-yl)pyridine
• CAS: 1332508-37-8
• 化学式: C₁₁H₁₅N
• 分子量: 161.247
• InChiKey: RVRZUIOAQFINGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(3,3-Dimethylbut-1-en-2-yl)pyridine 在 bis(1,5-cyclooctadiene)diiridium(I) dichloride 、 6-[[(3aR,5S,6S,6aR)-5-[(2,6-dimethylphenyl)sulfanylmethyl]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-yl]oxy]-2,4,8,10-tetratert-butylbenzo[d][1,3,2]benzodioxaphosphepine 、 氢气 、 四(3,5-二(三氟甲基)苯基)硼酸钠 作用下， 以 二氯甲烷 为溶剂， 20.0 ℃ 、100.0 kPa 条件下， 反应 4.0h， 以100%的产率得到3-[(2R)-3,3-dimethylbutan-2-yl]pyridine
  参考文献：
  名称：

  Thioether-phosphite: new ligands for the highly enantioselective Ir-catalyzed hydrogenation of minimally functionalized olefins

  摘要：

  我们描述了非氮捐赠者异配体——硫醚-磷酸酯配体——在铱催化的最小功能化烯烃氢化中的第一次成功应用。在标准条件下，对于一系列底物，包括具有挑战性的末端二取代底物，获得了极好的对映选择性（对映体过量高达99%）。

  DOI：

  10.1039/c1cc13300d

文献信息

• PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS
  申请人：Zask Arie

  公开号：US20080234262A1

  公开（公告）日：2008-09-25

  The present invention relates to Pyrazolopyrimidine Analogs, methods of making Pyrazolopyrimidine Analogs, compositions comprising a Pyrazolopyrimidine Analog, and methods for treating mTOR-related disorders comprising administering to a subject in need thereof an effective amount of a Pyrazolopyrimidine Analog. The invention also relates to treating PI3K-related disorders comprising administering to a subject in need thereof an effective amount of a Pyrazolopyrimidine Analog.

  本发明涉及吡唑吡嘧啶类似物，制备吡唑吡嘧啶类似物的方法，包含吡唑吡嘧啶类似物的组合物，以及治疗mTOR相关疾病的方法，包括向需要的受试者施用有效量的吡唑吡嘧啶类似物。该发明还涉及治疗PI3K相关疾病的方法，包括向需要的受试者施用有效量的吡唑吡嘧啶类似物。
• INTRACELLULAR KINASE INHIBITORS
  申请人：MannKind Corporation

  公开号：US20140080833A1

  公开（公告）日：2014-03-20

  Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs.

  细胞内激酶抑制剂及其治疗用于T细胞恶性肿瘤、B细胞恶性肿瘤、自身免疫性疾病和移植器官的患者。
• COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY
  申请人：Siddiqui M. Arshad

  公开号：US20110123435A1

  公开（公告）日：2011-05-26

  The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity. Formula I
• SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS
  申请人：Siddiqui M. Arshad

  公开号：US20120070370A1

  公开（公告）日：2012-03-22

  The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity.
• US8796460B2
  申请人：——

  公开号：US8796460B2

  公开（公告）日：2014-08-05